Skip to main content
MapleLMS Implementation
Conferences and Meetings 908. Outcomes Research: Myeloid Malignancies: Poster III

908. Outcomes Research: Myeloid Malignancies: Poster III

Short name: 908. Outcomes Research: Myeloid Malignancies: Poster III
Course start date: 11/05/2025

Sections

General
0 activities

Outcomes of Hematopoietic Stem Cell Transplantation in Patients Aged 70 Years and Older
Estimating the Prevalence of Possible Undiagnosed Chronic Myelomonocytic Leukemia in the General Population: An Nhanes Analysis
Real-World Treatment Patterns, Resource Utilization, and Cost of Care in Medicare Beneficiaries Newly Diagnosed with Acute Myeloid Leukemia and Treated with Venetoclax-Based Regimens
Largest Real-World Evaluation of Treatment Regimens and Clinical Outcomes Among Patients with Acute Promyelocytic Leukemia in the US: Data from the Command Consortium
Real-World Experience of Patients and Caregivers with Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis
Impact of Molecular Ontogeny on Hematological Recovery in AML Patients Treated with Hypomethylating Agent Plus Venetoclax Therapy
Outcomes with Real-World Use of Azacitidine and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Are Comparable to Long-Term Viale-a Results
Clinical Presentation and Induction Outcomes Among Hispanic and Non-Hispanic Patients with Acute Promyelocytic Leukemia
Indirect Treatment Comparison of Ivosidenib and Other Therapies in Patients with Newly Diagnosed Acute Myeloid Leukemia
Impact of Social Determinants of Health on Overall Survival in Patients with AML By European Leukemianet Risk Group
Italian Real-World Experience of Gilteritinib Monotherapy in Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: Preliminary Results
Real-World Use Patterns and Clinical Outcomes for Myelodysplastic Syndrome Patients Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents
Incidence of Erdheim-Chester Disease in the United States
Treatment Patterns of Ropeginterferon Alfa-2b-Njft in the Real-World Setting
What Is the Prognostic Relevance of Responses Less Than a CR(Sub-CR) to Initial AML Treatment?
Assessing the Impact of COVID-19 on Outcomes of Patients with Acute Myeloid Leukemia
Incidence and Risk of Therapy-Related Myeloid Neoplasms in Non-Myeloid Hematological Malignancies: A National Population-Based Matched Cohort Study
Erythropoietin Stimulating Agents and Risk of Cardiovascular Events in Older Patients with Myelodysplastic Syndromes
Disparities in AML Survival in the Targeted Therapy Era: Real World Evidence of Enhanced Equity of Outcomes for Patients in Medically Underserved Areas
FLT3 Inhibitors As Maintenance Therapy Post Allogenic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients with FLT3 Mutations; A Systematic Review and Meta-Analysis
Impact of Sociodemographic Factors on Mortality in Acute Myeloid Leukemia in the United States: A Time-Trend Analysis
Disparities in Clinical Outcomes in Patients with Newly Diagnosed Acute Myeloid Leukemia Treated in Public Versus Private Services in Brazil: Analysis of the Brazilian Acute Myeloid Leukemia Registry
Living with CML: A Qualitative Analysis